Trading halt would be the smart thing here. Instead, usual incompetence sees farcicle announcement and the share price drop below 10c. Well done Newsat team.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%